81 filings
Page 2 of 5
8-K
krz7kk8jug1w7oj6w
10 Nov 22
Iterum Therapeutics Reports Third Quarter 2022 Financial Results
7:15am
8-K
qfzl7lhd r1
20 Oct 22
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
8:00am
8-K
lupgcov8ja 5jarb
19 Sep 22
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
8:33am
8-K
q72zaihmey2wcpxkhxv
18 Aug 22
Material Modifications to Rights of Security Holders
6:03pm
8-K
sopvlzpi
12 Aug 22
Iterum Therapeutics Reports Second Quarter 2022 Financial Results
7:15am
8-K
ecox6gmohm03
28 Jul 22
Other Events
5:01pm
8-K
y9k0gjaedbvuou4
11 Jul 22
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA
8:01am
8-K
yae9p
8 Jul 22
Share Option Cancellation Agreement
5:00pm
8-K
polvbj0hpe32mfq93ov
16 Jun 22
Submission of Matters to a Vote of Security Holders
8:15am
8-K
1rv1la129o e2p0vsx
13 May 22
Iterum Therapeutics Reports First Quarter 2022 Financial Results
7:16am
8-K
tuixp 0uw64
28 Mar 22
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
7:15am
8-K
1uy6fy ctt8
12 Nov 21
Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
7:30am
8-K
1cg0h0n9
10 Sep 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:17pm
8-K
pamhq2
13 Aug 21
Iterum Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
7:15am
8-K
oc2z64
26 Jul 21
Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem
4:05pm
8-K
0s5cntj g876o
2 Jul 21
Iterum Therapeutics Provides Regulatory Update
7:00am
8-K
eze7v68jpvifsmwfk1l
23 Jun 21
Departure of Directors or Certain Officers
4:01pm
8-K
j9nhw6o4 9i
14 Jun 21
Departure of Directors or Certain Officers
4:40pm
8-K
rozll3m6xbf
27 May 21
Iterum Therapeutics Provides Update on NDA Review
5:15pm
8-K
w9aborylksj2a9efe
14 May 21
Iterum Therapeutics Reports First Quarter 2021 Financial Results
7:15am